PDF(Pubmed)
Abstract：
Persons with substance use disorder are at increased risk for hepatitis B virus (HBV) infection. Although most of them are attached to social health centers, the vaccination rate in this group is low. In this context, we designed a study to evaluate the prevalence of users of drug addiction centers (DAC) not immunized against hepatitis B and to compare the rate of vaccination against hepatitis B with the rate of immunization against SARS-Cov-2 in 2 years of follow-up.
Retrospective study that included individuals attended at DAC. Patients were screened at baseline (June 2020-January 2021) for HBV immunization. Individuals with HBsAb < 10 IU/mL were recommended to receive hepatitis B vaccine, during follow-up (January 2021-October 2022). At the end of follow-up, the HBV vaccination rate among candidates was determined and compared with the vaccination rate against SARS-Cov-2 in this population in the same period.
A total of 325 subjects were surveyed and tested. At baseline, the 65% (211/325) of were candidates to initiate vaccination and were advisor to HBV vaccination. During the follow-up 15 individuals received at least one dose of HBV vaccine, supposing a vaccination rate of 7.2%. In the same period, 186 individuals received at least one dose against SARS-Cov-2, representing a vaccination rate of 83%. The comparison between vaccination rates reached statistically significant (p < 0.001).
Our study manifests a low rate of immunization against HBV in DAC users, despite a high level of immunization for SARS-Cov-2 during the same period in the same population. Consequently, the lack of immunization against HVB in this population might be related with health policy issue more than to individuals linked to care and awareness. A similar approach for vaccination intended for SARS-CoV2 should be applied in high-risk population to warrant the success of immunization program against other preventable diseases such as HBV.
Retrospective study that included individuals attended at DAC. Patients were screened at baseline (June 2020-January 2021) for HBV immunization. Individuals with HBsAb < 10 IU/mL were recommended to receive hepatitis B vaccine, during follow-up (January 2021-October 2022). At the end of follow-up, the HBV vaccination rate among candidates was determined and compared with the vaccination rate against SARS-Cov-2 in this population in the same period.
A total of 325 subjects were surveyed and tested. At baseline, the 65% (211/325) of were candidates to initiate vaccination and were advisor to HBV vaccination. During the follow-up 15 individuals received at least one dose of HBV vaccine, supposing a vaccination rate of 7.2%. In the same period, 186 individuals received at least one dose against SARS-Cov-2, representing a vaccination rate of 83%. The comparison between vaccination rates reached statistically significant (p < 0.001).
Our study manifests a low rate of immunization against HBV in DAC users, despite a high level of immunization for SARS-Cov-2 during the same period in the same population. Consequently, the lack of immunization against HVB in this population might be related with health policy issue more than to individuals linked to care and awareness. A similar approach for vaccination intended for SARS-CoV2 should be applied in high-risk population to warrant the success of immunization program against other preventable diseases such as HBV.
摘要：
■患有物质使用障碍的人感染乙型肝炎病毒（HBV）的风险增加。尽管他们中的大多数都隶属于社会健康中心，这一组的疫苗接种率很低。在这种情况下，我们设计了一项研究,以评估未接种乙型肝炎疫苗的吸毒中心(DAC)使用者的患病率,并在2年的随访中比较乙型肝炎疫苗接种率和SARS-Cov-2疫苗接种率.
■包括参加DAC的个人的回顾性研究。患者在基线（2020年6月至2021年1月）筛查HBV免疫。HBsAb<10IU/mL的个人建议接受乙肝疫苗，随访期间（2021年1月至2022年10月）。在后续行动结束时，本研究确定了候选人群的HBV疫苗接种率,并与同期该人群的SARS-Cov-2疫苗接种率进行了比较.
■总共对325名受试者进行了调查和测试。在基线,其中65%(211/325)是启动疫苗接种的候选人,也是HBV疫苗接种的顾问.在随访过程中，15个人接受了至少一剂HBV疫苗，假设疫苗接种率为7.2%。在同一时期,186人接受了至少一剂针对SARS-Cov-2的疫苗接种率为83％。疫苗接种率之间的比较达到统计学显著(p<0.001)。
■我们的研究表明，DAC使用者的HBV免疫接种率较低，尽管同一时期在同一人群中对SARS-Cov-2的免疫水平很高。因此,该人群中缺乏针对HVB的免疫接种可能与卫生政策问题有关,而不是与护理和意识相关的个人.应在高风险人群中应用针对SARS-CoV2的类似疫苗接种方法，以保证针对HBV等其他可预防疾病的免疫计划的成功。
■包括参加DAC的个人的回顾性研究。患者在基线（2020年6月至2021年1月）筛查HBV免疫。HBsAb<10IU/mL的个人建议接受乙肝疫苗，随访期间（2021年1月至2022年10月）。在后续行动结束时，本研究确定了候选人群的HBV疫苗接种率,并与同期该人群的SARS-Cov-2疫苗接种率进行了比较.
■总共对325名受试者进行了调查和测试。在基线,其中65%(211/325)是启动疫苗接种的候选人,也是HBV疫苗接种的顾问.在随访过程中，15个人接受了至少一剂HBV疫苗，假设疫苗接种率为7.2%。在同一时期,186人接受了至少一剂针对SARS-Cov-2的疫苗接种率为83％。疫苗接种率之间的比较达到统计学显著(p<0.001)。
■我们的研究表明，DAC使用者的HBV免疫接种率较低，尽管同一时期在同一人群中对SARS-Cov-2的免疫水平很高。因此,该人群中缺乏针对HVB的免疫接种可能与卫生政策问题有关,而不是与护理和意识相关的个人.应在高风险人群中应用针对SARS-CoV2的类似疫苗接种方法，以保证针对HBV等其他可预防疾病的免疫计划的成功。
